DE69127175D1 - Antisens-Oligonukleotide zur Behandlung von Krebs - Google Patents

Antisens-Oligonukleotide zur Behandlung von Krebs

Info

Publication number
DE69127175D1
DE69127175D1 DE69127175T DE69127175T DE69127175D1 DE 69127175 D1 DE69127175 D1 DE 69127175D1 DE 69127175 T DE69127175 T DE 69127175T DE 69127175 T DE69127175 T DE 69127175T DE 69127175 D1 DE69127175 D1 DE 69127175D1
Authority
DE
Germany
Prior art keywords
antisense oligonucleotides
cancer
treatment
animals
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69127175T
Other languages
English (en)
Other versions
DE69127175T2 (de
Inventor
S Cho-Chung Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69127175D1 publication Critical patent/DE69127175D1/de
Application granted granted Critical
Publication of DE69127175T2 publication Critical patent/DE69127175T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
DE69127175T 1990-11-02 1991-10-31 Antisens-Oligonukleotide zur Behandlung von Krebs Expired - Fee Related DE69127175T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60711390A 1990-11-02 1990-11-02
US68019891A 1991-04-05 1991-04-05
US07/702,163 US5271941A (en) 1990-11-02 1991-05-20 Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases

Publications (2)

Publication Number Publication Date
DE69127175D1 true DE69127175D1 (de) 1997-09-11
DE69127175T2 DE69127175T2 (de) 1998-03-12

Family

ID=27416969

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69127175T Expired - Fee Related DE69127175T2 (de) 1990-11-02 1991-10-31 Antisens-Oligonukleotide zur Behandlung von Krebs
DE69132299T Expired - Fee Related DE69132299T2 (de) 1990-11-02 1991-10-31 Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69132299T Expired - Fee Related DE69132299T2 (de) 1990-11-02 1991-10-31 Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs

Country Status (9)

Country Link
US (3) US5271941A (de)
EP (3) EP0785252B1 (de)
KR (1) KR0171210B1 (de)
AT (2) ATE156517T1 (de)
CA (2) CA2488792A1 (de)
DE (2) DE69127175T2 (de)
DK (2) DK0785252T3 (de)
ES (2) ES2148838T3 (de)
GR (2) GR3024673T3 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5646267A (en) * 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US6995146B2 (en) * 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
WO1994022486A1 (en) 1993-03-26 1994-10-13 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5639872A (en) * 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
WO1995008350A1 (en) * 1993-09-20 1995-03-30 Reed John C REGULATION OF bcl-2 GENE EXPRESSION
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6608035B1 (en) * 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US6624293B1 (en) * 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide
US7074768B2 (en) * 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US20050054600A1 (en) * 1995-08-17 2005-03-10 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
DE69835886D1 (de) * 1997-03-12 2006-10-26 Idera Pharmaceuticals Inc Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6312941B1 (en) 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
WO2000079281A1 (en) * 1999-06-18 2000-12-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6489356B2 (en) 2000-09-05 2002-12-03 Edward Leung Method for treating pain in humans
US7312325B2 (en) 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
AU9684601A (en) 2000-10-12 2002-04-22 Univ Rochester Compositions that inhibit proliferation of cancer cells
KR100408916B1 (ko) * 2000-11-23 2003-12-11 주식회사 바이오제니아 마이코락톤을 함유하는 항암제, 사람 레티노블라스토마단백질의 발현을 저하시키는 안티센스 올리고누클레오티드및 마이코락톤과 상기 안티센스 올리고누클레오티드를함유하는 항암제
US6524854B1 (en) * 2001-09-11 2003-02-25 Isis Pharmaceuticals, Inc. Antisense inhibition of PKA regulatory subunit RII alpha expression
ATE469167T1 (de) 2002-02-06 2010-06-15 Vicor Technologies Inc Anti-infarkt-moleküle
EP1534729A2 (de) * 2002-02-26 2005-06-01 University of Utah Research Foundation Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US7528117B2 (en) * 2002-12-05 2009-05-05 The Research Foundation Of State University Of New York High efficacy antisense RIαPKA poly-DNP oligoribonucleotides
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
WO2005115405A1 (en) * 2004-04-28 2005-12-08 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
WO2005112978A2 (en) 2004-05-21 2005-12-01 University Of Utah Research Foundation Methods and compositions related to delivery of chemical compounds to invertebrate embryos
EP1782321A4 (de) 2004-07-23 2009-11-04 Univ North Carolina Verfahren und materialien zur bestimmung von schmerzempfindlichkeit und vorhersage und behandlung zugehöriger störungen
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
US8703769B2 (en) * 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007047512A2 (en) 2005-10-14 2007-04-26 Musc Foundation For Research Development Inhibition of pax2 by defb1 induction as a therapy for cancer
EP3342415B1 (de) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur und verwendung von 5´-phosphat-oligonukleotiden
AU2007297535C1 (en) 2006-09-21 2017-11-23 University Of Florida Research Foundation, Inc. Compositions and methods related to protein displacement therapy for myotonic distrophy
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
CA2672297A1 (en) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
EP2030615A3 (de) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen
EP2195331B1 (de) 2007-08-28 2013-11-20 Uab Research Foundation Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
US8501912B2 (en) * 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
US8816095B2 (en) * 2008-08-15 2014-08-26 Georgetown University Na channels, disease, and related assays and compositions
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
US9970002B2 (en) 2012-12-12 2018-05-15 Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
CN105960410B (zh) 2013-11-21 2020-12-04 硒瑞恩生物科技有限公司 硒衍生的核酸复合物的结构测定方法
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
SG11201706293XA (en) * 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
JP6772156B2 (ja) 2015-02-04 2020-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 治療用分子を選択する方法
CN109563516B (zh) 2016-07-28 2023-10-27 雷杰纳荣制药公司 Gpr156变体及其用途
WO2018026943A1 (en) 2016-08-03 2018-02-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tlr9 targeted therapeutics
SG11201905508VA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hsd17b13 variants and uses thereof
MX2019014661A (es) 2017-06-05 2020-07-29 Regeneron Pharma Variantes de b4galt1 y usos de estas.
CA3074652A1 (en) 2017-09-06 2019-03-14 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
CA3074682A1 (en) 2017-09-07 2019-03-14 Regeneron Pharmaceuticals, Inc. Solute carrier family 14 member 1 (slc14a1) variants and uses thereof
CA3078883A1 (en) 2017-10-11 2019-04-18 Regeneron Pharmaceuticals, Inc. Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
JP2021501601A (ja) 2017-10-16 2021-01-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． コルヌリン（ｃｒｎｎ）バリアント及びその使用
MA56457A (fr) 2019-07-02 2022-05-11 Regeneron Pharma Modulateurs de hsd17b13 et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
NO864301L (no) * 1986-10-28 1988-04-29 Tore Jahnsen Dna-prober for human regulatorisk enhet av camp-avhengige proteinkinaser.
DE68926455T2 (de) * 1988-07-05 1996-10-31 Baylor College Medicine Verfahren zur identifizierung von bakterien
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases

Also Published As

Publication number Publication date
KR0171210B1 (ko) 1999-02-01
DE69132299T2 (de) 2001-02-15
ES2148838T3 (es) 2000-10-16
CA2054325A1 (en) 1992-05-03
EP0785252A1 (de) 1997-07-23
CA2488792A1 (en) 1992-05-03
DK0490077T3 (da) 1998-01-26
DE69127175T2 (de) 1998-03-12
EP0490077B1 (de) 1997-08-06
US5691317A (en) 1997-11-25
ATE194383T1 (de) 2000-07-15
GR3034535T3 (en) 2001-01-31
EP0972831A1 (de) 2000-01-19
DE69132299D1 (de) 2000-08-10
GR3024673T3 (en) 1997-12-31
EP0785252B1 (de) 2000-07-05
DK0785252T3 (da) 2000-10-02
US5271941A (en) 1993-12-21
CA2054325C (en) 2005-03-15
ATE156517T1 (de) 1997-08-15
EP0490077A1 (de) 1992-06-17
US5627158A (en) 1997-05-06
ES2104644T3 (es) 1997-10-16

Similar Documents

Publication Publication Date Title
DE69127175D1 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
DE69310634D1 (de) Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
HUT51594A (en) Process for production of celates and their complexes containing ortolizating functional groups, compositions containing such active substances and process for production of conjugates consisting of one complex and linked to it antibody or fragment of antibody
DE69429806D1 (de) Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DE69000960T2 (de) Zusammensetzung zur behandlung von pigmentierung.
DE69425345T2 (de) Anwendung von Selegilin in Tiermedizin
DE69111457T2 (de) Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien.
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
DE3782661D1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs.
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
DE58904510D1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.
RU95106650A (ru) Фармацевтические композиции для предотвращения образования метастазов рака в печени и фармацевтическая композиция для лечения рака печени, способ лечения, способ получения композиции, применение цитарабин окфосфата для получения фармацевтической композиции

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee